Human Nasal and Lung Tissues Infected Ex Vivo with SARS-CoV-2 Provide Insights into Differential Tissue-Specific and Virus-Specific Innate Immune Responses in the Upper and Lower Respiratory Tract

Abstract

The nasal-mucosa constitutes the primary entry site for respiratory viruses including SARS-CoV-2. While the imbalanced innate immune response of end-stage COVID-19 has been extensively studied, the earliest stages of SARS-CoV-2 infection at the mucosal entry site have remained unexplored. Here we employed SARS-CoV-2 and influenza virus infection in native multi-cell-type human nasal turbinate and lung tissues ex vivo , coupled with genome-wide transcriptional analysis, to investigate viral susceptibility and early patterns of local-mucosal innate immune response in the authentic milieu of the human respiratory tract. SARS-CoV-2 productively infected the nasal turbinate tissues, predominantly targeting respiratory epithelial cells, with rapid increase in tissue-associated viral sub-genomic mRNA, and secretion of infectious viral progeny. Importantly, SARS-CoV-2 infection triggered robust antiviral and inflammatory innate immune responses in the nasal mucosa. The upregulation of interferon stimulated genes, cytokines and chemokines, related to interferon signaling and immune-cell activation pathways, was broader than that triggered by influenza virus infection. Conversely, lung tissues exhibited a restricted innate immune response to SARS-CoV-2, with a conspicuous lack of type I and III interferon upregulation, contrasting with their vigorous innate immune response to influenza virus. Our findings reveal differential tissue-specific innate immune responses in the upper and lower respiratory tract, that are distinct to SARS-CoV-2. The studies shed light on the role of the nasal-mucosa in active viral transmission and immune defense, implying a window of opportunity for early interventions, whereas the restricted innate immune response in early-SARS-CoV-2-infected lung tissues could underlie the unique uncontrolled late-phase lung damage of advanced COVID-19. IMPORTANCE In order to reduce the late-phase morbidity and mortality of COVID-19, there is a need to better understand and target the earliest stages of SARS-CoV-2 infection in the human respiratory tract. Here we have studied the initial steps of SARS-CoV-2 infection and the consequent innate immune responses within the natural multicellular complexity of human nasal-mucosal and lung tissues. Comparing the global innate response patterns of nasal and lung tissues, infected in parallel with SARS-CoV-2 and influenza virus, we have revealed distinct virus-host interactions in the upper and lower respiratory tract, which could determine the outcome and unique pathogenesis of SARS-CoV-2 infection. Studies in the nasal-mucosal infection model can be employed to assess the impact of viral evolutionary changes, and evaluate new therapeutic and preventive measures against SARS-CoV-2 and other human respiratory pathogens.

Differential Co-Expression Network Analysis Reveals Key Hub-High Traffic Genes as Potential Therapeutic Targets for COVID-19 Pandemic

“…Therefore, inhibitory mechanisms to target ribosome-SARS-CoV-2 interactions may be used to treat COVID-19 ( 331 ). Additionally, some pink module hub-high traffic genes, such as RPL9 , RPS27A , RPL26 , RPS12 ( 336 ), RPS6 ( 228 ), RPL5 , RPL7 ( 337 ), RPGR ( 173 ), and RPS20 ( 338 ) were highly enriched in the ribosome pathway and involved in SARS-CoV-2-ribosome interactions. For example, the increase in ribosomal protein L9 ( RPL9 ) expression was attributed to SARS-CoV-2 hijacking the host translation machine ( 339 ).…”

SARS-CoV-2 non-structural protein 6 triggers NLRP3-dependent pyroptosis by targeting ATP6AP1

“…Bulk RNA-Seq data of lung tissue of COVID-19 patients or uninfected individuals were downloaded within the series GSE171668 [ 49 ] and GSE175779, respectively. RNA-Seq raw reads of patients infected with SARS-CoV-2 for quantitating NSP6 expression level were derived from the series GSE163959 [ 50 ]. RNA sequencing data were first evaluated by FastQC with the default parameter and then aligned with Hisat2 against the human (GRCh38) genome and SARS-CoV-2 genome (NC_045512) guided by GENCODE gene annotation and NCBI RefSeq SARS-CoV-2 genome annotation with the default parameter.…”

Viral Interference between Respiratory Viruses

“…SARS-CoV-2 was shown to trigger a broader up-regulation of ISGs, cytokines and chemokines in the human nasal mucosa than pH1N1 virus ( 46 ). However, contrarily to influenza virus, SARS-CoV-2 fails to induce an early IFN-I and IFN-III response in human lung tissues, leading to a late and vigorous inflammatory response.…”